The acquiring companies will each own an equal share of the majority stake. The transaction is expected to close by the end of the year.

Headquartered in Durham, North Carolina, Alcami offers various capabilities, including sterile fill&finish of biologics and small molecules, formulation development, laboratory services and the cGMP biostorage of high-value temperature-sensitive biologics, pharmaceuticals and materials.

“We believe Alcami represents a unique opportunity to acquire a rapidly growing CDMO with complementary capabilities in attractive markets,” said Mike Mortimer and Alan Mackay, managing partners of GHO Capital. “The company is set to accelerate its growth and leveraging our specialist expertise, we are delighted to be supporting them to diversify its product and service mix, pushing into new markets such as Europe.”

MDP and Ampersand bought Alcami from Antares Capital on Jun. 1, 2018. Under their ownership, Alcami has made two acquisitions—TriPharm Services in January 2020 and Masy BioServices in December 2021. TriPharm added a sterile fill&finish manufacturing center near the Research Triangle Park in North Carolina, while Masy added four cGMP biostorage facilities in Massachusetts.

Alcami has also invested more than $140 million in recent years to add five sterile fill&finish manufacturing lines and extra laboratory space to support both biologic and small molecule programs. The CDMO operates five scientific campuses across the US.

Author: Elaine Burridge, Freelance Journalist